AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24977638 — intervention group
Group type: COMPARATOR
Intervention: Moderate neuromuscular blockade
Number of subjects: 48
Study 22175765 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE ≥0.35 kU(A)/l for hazelnut
Number of subjects: 151
Study 22175765 — intervention group
Group type: EXPERIMENTAL
Intervention: rCor a 1 spiking of the ImmunoCAP
Number of subjects: 151
Study 22175765 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE cutoff of 26 kU(A)/l
Number of subjects: 151
Study 22175765 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) for hazelnut
Number of subjects: 151
Study 22175765 — intervention group
Group type: EXPERIMENTAL
Intervention: History of accidental ingestion leading to an allergic reaction to hazelnut
Number of subjects: 151
Study 20179669 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1 g per day) plus dietary treatment
Number of subjects: 50
Study 20179669 — intervention group
Group type: COMPARATOR
Intervention: Dietary treatment alone
Number of subjects: 50
Study 17920338 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg 3 times a day for 6 weeks
Number of subjects: 24
Study 17920338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 15704047 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice daily
Number of subjects: 120
Study 15704047 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice daily plus omeprazole 20 mg once daily
Number of subjects: 120
Study 15704047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 12842242 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 25 mg once daily
Number of subjects: 400
Study 12842242 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg once daily
Number of subjects: 400
Study 12842242 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 100 mg once daily
Number of subjects: 400
Study 12842242 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 200 mg once daily
Number of subjects: 400
Study 12842242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 12579651 — intervention group
Group type: EXPERIMENTAL
Intervention: Alomide eyedrops
Number of subjects: 0
Study 12579651 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate eyedrops
Number of subjects: 0
Study 8885731 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbutaline (5 mg orally, every 4 hours)
Number of subjects: 203
Study 8885731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 8885731 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbutaline
Number of subjects: 203
Study 1676245 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 12
Study 1676245 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 12
Study 6360923 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening Primrose Oil (EPO)
Number of subjects: 100
Study 6360923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31884078 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message link to online survey
Number of subjects: 110
Study 30677788 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2928057 600 mg
Number of subjects: 0
Study 30677788 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3113593 150 mg
Number of subjects: 0
Study 30677788 — intervention group
Group type: COMPARATOR
Intervention: LY2928057
Number of subjects: 0
Study 30677788 — intervention group
Group type: COMPARATOR
Intervention: LY3113593
Number of subjects: 0
Study 28070770 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate dance intervention (10 private weekly dance lessons and 2 practice parties over 12 weeks)
Number of subjects: 31
Study 27245158 — intervention group
Group type: EXPERIMENTAL
Intervention: Getting To Outcomes (GTO) implementation support intervention
Number of subjects: 32
Study 27245158 — intervention group
Group type: COMPARATOR
Intervention: Making Proud Choices (MPC) control group
Number of subjects: 32
Study 23819494 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional per-beam IMRT QA with gantry angle of 0
Number of subjects: 10
Study 23819494 — intervention group
Group type: COMPARATOR
Intervention: Conventional per-beam IMRT QA with gantry at specific angles
Number of subjects: 10
Study 22006197 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Bearing (MB) TKA
Number of subjects: 416
Study 22006197 — intervention group
Group type: COMPARATOR
Intervention: Fixed Bearing (FB) TKA
Number of subjects: 416
Study 19710342 — intervention group
Group type: EXPERIMENTAL
Intervention: Female partners of circumcised men; 11 out of 15 (73.3%) had ulcers due to HSV-2 or other pathogens.
Number of subjects: 40
Study 19710342 — intervention group
Group type: COMPARATOR
Intervention: Female partners of uncircumcised men; 15 out of 25 (60.0%) had ulcers due to HSV-2 or other pathogens.
Number of subjects: 40
Study 17924278 — intervention group
Group type: EXPERIMENTAL
Intervention: Spoken output
Number of subjects: 0
Study 17924278 — intervention group
Group type: EXPERIMENTAL
Intervention: Written responding
Number of subjects: 0
Study 17924278 — intervention group
Group type: COMPARATOR
Intervention: Low output interference
Number of subjects: 0
Study 17924278 — intervention group
Group type: COMPARATOR
Intervention: High output interference
Number of subjects: 0
Study 15141930 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive peer recommendations
Number of subjects: 94
Study 15141930 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative peer recommendations
Number of subjects: 94
Study 15141930 — intervention group
Group type: COMPARATOR
Intervention: Anticipation of providing evaluations
Number of subjects: 94
Study 12597061 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux (2.5 mg once daily, subcutaneous, starting postoperatively)
Number of subjects: 0
Study 12597061 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin (control group)
Number of subjects: 0
Study 12597061 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 0
Study 12597061 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux and Enoxaparin
Number of subjects: 0
Study 10569656 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels
Number of subjects: 1172
Study 8913184 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical antireflux therapy (ranitidine plus cisapride)
Number of subjects: 24
Study 8913184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1991415 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 percent semisolid gel
Number of subjects: 24
Study 1991415 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall percent evacuation of three stool consistencies after IPAA
Number of subjects: 24
Study 1991415 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid stool consistency
Number of subjects: 24
Study 1991415 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 1991415 — intervention group
Group type: EXPERIMENTAL
Intervention: IPAA group
Number of subjects: 24
Study 6856646 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (16 mg, 32 mg, 48 mg)
Number of subjects: 4
Study 6856646 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaine (48 mg, 96 mg)
Number of subjects: 4
Study 6856646 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 4
Study 31297968 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg qd
Number of subjects: 302
Study 31297968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 29578090 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive internet cognitive‐behavioral therapy
Number of subjects: 0
Study 29578090 — intervention group
Group type: COMPARATOR
Intervention: Adjunctive internet education
Number of subjects: 0
Study 27488327 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (300,000 IU intramuscular)
Number of subjects: 90
Study 27488327 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (1 mL as placebo)
Number of subjects: 90
Study 23791016 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured withdrawal program (60 mcg/day for 15 days and then 60 mcg every second evening for another 15 days)
Number of subjects: 81
Study 23791016 — intervention group
Group type: COMPARATOR
Intervention: Abrupt withdrawal
Number of subjects: 81
Study 24308282 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored intervention including training on medication management, provision of evidence-based checklists, a tablet PC with an interactive educational tool, and information leaflets for patients.
Number of subjects: 0
Study 24308282 — intervention group
Group type: COMPARATOR
Intervention: Control practices providing care as usual without special training.
Number of subjects: 0
Study 20495250 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium staples
Number of subjects: 12
Study 20495250 — intervention group
Group type: COMPARATOR
Intervention: Mini-titanium plate with oblique screw
Number of subjects: 12
Study 18832497 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antidepressants
Number of subjects: 27
Study 18832497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 18832497 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (second-generation antidepressants)
Number of subjects: 27
Study 16877896 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (4-6 mg/day)
Number of subjects: 757
Study 16877896 — intervention group
Group type: COMPARATOR
Intervention: Conventional antipsychotics (haloperidol 10 or 20 mg/day, perphenazine mean dose 28 mg/day, zuclopenthixol mean dose 38 mg/day)
Number of subjects: 757
Study 16877896 — intervention group
Group type: COMPARATOR
Intervention: Conventional antipsychotics
Number of subjects: 757
Study 12512025 — intervention group
Group type: EXPERIMENTAL
Intervention: EP-1 antagonist ZD6416
Number of subjects: 12
Study 12512025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12512025 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 12
Study 11789207 — intervention group
Group type: EXPERIMENTAL
Intervention: Yimai Jiangya extract (YMJYE)
Number of subjects: 42
Study 11789207 — intervention group
Group type: COMPARATOR
Intervention: Captopril (control group)
Number of subjects: 42
Study 11789207 — intervention group
Group type: COMPARATOR
Intervention: Yimai Jiangya extract (YMJYE) and Captopril (control group)
Number of subjects: 42
Study 9013269 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglycerides
Number of subjects: 1726
Study 9013269 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cholesterol
Number of subjects: 1726
Study 9013269 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid fractions
Number of subjects: 1726
Study 1390969 — intervention group
Group type: EXPERIMENTAL
Intervention: Both exercise and wax bath
Number of subjects: 52
Study 1390969 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise only
Number of subjects: 52
Study 1390969 — intervention group
Group type: EXPERIMENTAL
Intervention: Wax bath only
Number of subjects: 52
Study 1390969 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study 3864167 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) infusion therapy (100 micrograms/day, 3-hour intravenous infusion for three weeks)
Number of subjects: 9
Study 3864167 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 9
Study 31640191 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 0
Study 31640191 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Number of subjects: 0
Study 30430724 — intervention group
Group type: COMPARATOR
Intervention: Single 2-g oral dose of TXA 2 h preoperatively followed by 1 g of oral TXA 3 h postoperatively (group B)
Number of subjects: 275
Study 30430724 — intervention group
Group type: COMPARATOR
Intervention: Single dose followed by 1 g of oral TXA 3 h and 7 h postoperatively (group C)
Number of subjects: 275
Study 30430724 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose followed by 1 g of oral TXA 3 h, 7 h and 11 h postoperatively (group D)
Number of subjects: 275
Study 30430724 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose followed by 1 g of oral TXA 3 h, 7 h, 11 h and 15 h postoperatively (group E)
Number of subjects: 275
Study 30430724 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group A)
Number of subjects: 275
Study 26937860 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive nurse participation in family conferences led by a physician
Number of subjects: 100
Study 26937860 — intervention group
Group type: COMPARATOR
Intervention: Control group with conferences led by a physician without a nurse
Number of subjects: 100
Study 25527165 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% pure glucose
Number of subjects: 96
Study 25527165 — intervention group
Group type: COMPARATOR
Intervention: 0.2% polidocanol diluted in 70% glucose
Number of subjects: 96
Study 22833405 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of bone marrow-derived mononucleated cells (BM-MNC)
Number of subjects: 60
Study 22833405 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BM-MNC treatment)
Number of subjects: 60
Study 20384942 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 0
Study 20384942 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 0
Study 20384942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18541126 — intervention group
Group type: EXPERIMENTAL
Intervention: NSPN extract (360 mg Nigella sativa and 50 mg Phyllanthus niruri), administered 3 times daily for 7 days
Number of subjects: 200
Study 18541126 — intervention group
Group type: EXPERIMENTAL
Intervention: NSPN extract
Number of subjects: 200
Study 18541126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 15933495 — intervention group
Group type: EXPERIMENTAL
Intervention: Splinting
Number of subjects: 138
Study 15933495 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 138
Study 15933495 — intervention group
Group type: EXPERIMENTAL
Intervention: NCS parameters
Number of subjects: 138
Study 12601404 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated chronic care management programme
Number of subjects: 0
Study 12601404 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based care processes
Number of subjects: 0
Study 10937982 — intervention group
Group type: EXPERIMENTAL
Intervention: Candoxatril 200 mg b.d. (n = 22)
Number of subjects: 60
Study 10937982 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25-50 mg b.d. (n = 23)
Number of subjects: 60
Study 10937982 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 60
Study 8656148 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol
Number of subjects: 2
Study 8656148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 8656148 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (after transplantation)
Number of subjects: 2
Study 8656148 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (2 years post-transplant)
Number of subjects: 2
Study 8433433 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion angioscopy
Number of subjects: 250
Study 8433433 — intervention group
Group type: COMPARATOR
Intervention: Completion angiography
Number of subjects: 250
Study 3315295 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous cardiac pacing (PACE) in addition to standard advanced cardiac life support (ACLS) treatment
Number of subjects: 202
Study 3315295 — intervention group
Group type: COMPARATOR
Intervention: Standard advanced cardiac life support (ACLS) care
Number of subjects: 202
Study 31943768 — intervention group
Group type: COMPARATOR
Intervention: TNF‐α polymorphisms (rs1799964)
Number of subjects: 327
Study 31943768 — intervention group
Group type: COMPARATOR
Intervention: TNF‐α polymorphisms (rs1800610)
Number of subjects: 327
Study 31943768 — intervention group
Group type: COMPARATOR
Intervention: TGTA haplotype
Number of subjects: 327
Study 31943768 — intervention group
Group type: COMPARATOR
Intervention: TGTG haplotype
Number of subjects: 327
Study 29843254 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide once weekly
Number of subjects: 0
Study 29843254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27294447 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrally Assisted Collaborative Telecare (CACT)
Number of subjects: 666
Study 27294447 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 666
Study 25270737 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipronged intervention including educational brochure, personalized letter reminder, research assistant call, reminder letter, and automated phone call.
Number of subjects: 521
Study 25270737 — intervention group
Group type: COMPARATOR
Intervention: Usual care with a form letter reminder and an automated reminder phone call.
Number of subjects: 521
Study 23566563 — intervention group
Group type: EXPERIMENTAL
Intervention: Let's Talk! intervention (n = 34)
Number of subjects: 66
Study 23566563 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 32)
Number of subjects: 66
Study 21760916 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer counselling for exclusive breastfeeding (EBF)
Number of subjects: 483
Study 21760916 — intervention group
Group type: COMPARATOR
Intervention: Control (no peer counselling for EBF)
Number of subjects: 483
Study 21760916 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 483
Study 21760916 — intervention group
Group type: EXPERIMENTAL
Intervention: Length-for-age Z (LAZ) scores among children supplemented with Vitamin A
Number of subjects: 483
Study 21760916 — intervention group
Group type: EXPERIMENTAL
Intervention: Length-for-age Z (LAZ) scores among children not supplemented with Vitamin A
Number of subjects: 483
Study 19322108 — intervention group
Group type: EXPERIMENTAL
Intervention: Pome fruit workers
Number of subjects: 0
Study 19322108 — intervention group
Group type: EXPERIMENTAL
Intervention: Final data collection
Number of subjects: 0
Study 19322108 — intervention group
Group type: COMPARATOR
Intervention: Non-pome fruit workers
Number of subjects: 0
Study 19322108 — intervention group
Group type: COMPARATOR
Intervention: Children of pome fruit workers
Number of subjects: 0
Study 19322108 — intervention group
Group type: COMPARATOR
Intervention: Children of non-pome fruit workers
Number of subjects: 0
Study 16714186 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted 30 microg formulation
Number of subjects: 300
Study 16714186 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted 7.5 microg, adjuvanted 15 microg, or non-adjuvanted 15 microg
Number of subjects: 300
Study 16714186 — intervention group
Group type: EXPERIMENTAL
Intervention: All formulations
Number of subjects: 300
Study 16714186 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant
Number of subjects: 300
Study 15274267 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous tenotomy
Number of subjects: 45
Study 15274267 — intervention group
Group type: COMPARATOR
Intervention: Open release
Number of subjects: 45
Study 11343051 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinblastine (6 mg/m², given intravenously every week)
Number of subjects: 143
Study 11343051 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (150 mg/m²/d, given intravenously for 3 days every 3 weeks)
Number of subjects: 143
Study 10342003 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring with propofol anaesthesia
Number of subjects: 80
Study 10342003 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring with sevoflurane anaesthesia
Number of subjects: 80
Study 10342003 — intervention group
Group type: COMPARATOR
Intervention: Control group (propofol without BIS monitoring)
Number of subjects: 80
Study 10342003 — intervention group
Group type: COMPARATOR
Intervention: Control group (sevoflurane without BIS monitoring)
Number of subjects: 80
Study 10342003 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 80
Study 7664216 — intervention group
Group type: COMPARATOR
Intervention: lisinopril (ACE inhibitor)
Number of subjects: 135
Study 7664216 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan (Ang II receptor antagonist)
Number of subjects: 135
Study 7664216 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide (thiazide diuretic)
Number of subjects: 135
Study 2570004 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg acrivastine three times daily
Number of subjects: 12
Study 2570004 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg terfenadine three times daily
Number of subjects: 12
Study 2570004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1071694 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorothiazide (0.5 g twice daily)
Number of subjects: 20
Study 1071694 — intervention group
Group type: EXPERIMENTAL
Intervention: Metolazone (5 mg daily)
Number of subjects: 20
Study 1071694 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorothiazide and Metolazone
Number of subjects: 20
Study 30732456 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 2539
Study 30732456 — intervention group
Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 2539
Study 30732456 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete revascularization after off-pump CABG
Number of subjects: 2539
Study 30732456 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete revascularization after off-pump CABG
Number of subjects: 2539
Study 30732456 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete revascularization after on-pump CABG
Number of subjects: 2539
Study 30732456 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete revascularization after on-pump CABG
Number of subjects: 2539
Study 30732456 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete revascularization
Number of subjects: 2539
Study 26974418 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 120